Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH

Medical Hypotheses

Volumn 84, Issue 5, 2015, Pages 490-493

  Takeuchi, M ^a   Sakasai Sakai, A ^a   Takata, T ^a   Ueda, T ^a   Takino, J ^b   Tsutsumi, M ^a   Hyogo, H ^c   Yamagishi, S ^d  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ATORVASTATIN; INSULIN; BIOLOGICAL MARKER;

ARTICLE; BLOOD LEVEL; DISEASE COURSE; GENE EXPRESSION; HUMAN; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; LIVER CELL; LIVER CELL CARCINOMA; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; STEATOSIS; STELLATE CELL; BIOLOGICAL MODEL; BLOOD; NON-ALCOHOLIC FATTY LIVER DISEASE;

BIOMARKERS; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MODELS, BIOLOGICAL; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84925710959     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.02.002     Document Type: Article

References (45)

1. Vuppalanchi R., Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009, 49:306-317.
2. Teli M.R., James O.F., Burt A.D., Bennett M.K., Day C.P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.
3. Dam-Larsen S., Franzmann M., Andersen I.B., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004, 53:750-755.
4. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
5. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
6. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
7. Hyogo H., Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 2008, 14:969-972.
8. Sullivan S. Implications of diet on nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010, 26:160-164.
9. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007, 47:711-717.
10. Ouyang X., Cirillo P., Sautin Y., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008, 48:993-999.
11. Abdelmalek M.F., Suzuki A., Guy C., et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1961-1971.
12. Assy N., Nasser G., Kamayse I., et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol 2008, 22:811-816.
13. Abid A., Taha O., Nseir W., Farah R., Grosovski M., Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 2009, 51:918-924.
14. Riby J.E., Fujisawa T., Kretchmer N. Fructose absorption. Am J Clin Nutr 1993, 58(Suppl.):748S-753S.
15. Oates P.J. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002, 50:325-392.
16. Maekawa K., Tanimoto T., Okada S. Gene expression of enzymes comprising the polyol pathway in various rat tissues determined by the competitive RT-PCR method. Jpn J Pharmacol 2002, 88:123-126.
17. Schalkwijk C.G., Stehouwer C.D., van Hinsbergh V.W. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev 2004, 20:369-382.
18. Gaby A.R. Adverse effects of dietary fructose. Altern Med Rev 2005, 10:294-306.
19. Takeuchi M., Yamagishi S. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Med Hypotheses 2004, 63:453-455.
20. Takeuchi M., Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimer Dis 2009, 16:845-858.
21. Takeuchi M., Takino J., Yamagishi S. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy. Curr Drug Targets 2010, 11:1468-1482.
22. Yoshida T., Yamagishi S., Nakamura K., et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006, 49:3094-3099.
23. Iwamoto K., Kanno K., Hyogo H., et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 2008, 43:298-304.
24. Hyogo H., Yamagishi S., Iwamoto K., et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22:1112-1119.
25. Kimura Y., Hyogo H., Yamagishi S., et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010, 45:750-757.
26. Bosch F.X., Ribes J., Díaz M., Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127(Suppl. 1):S5-S16.
27. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
28. Kan H., Yamagishi S., Ojima A., et al. Elevation of serum levels of advanced glycation end products in patients with non-B or non-C hepatocellular carcinoma. J Clin Lab Anal 2014, [Epub ahead of print]. 10.1002/jcla.21797.
29. James O., Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999, 353:1634-1636.
30. Day C.P., James O.F. Steatohepatitis: a tale of two 'hits'?. Gastroenterology 1998, 114:842-845.
31. Jinnouchi Y., Yamagishi S., Takeuchi M., et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006, 6:191-193.
32. Vilà L., Rebollo A., Adalsteisson G.S., et al. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol 2011, 251:32-40.
33. Sakuraoka Y., Sawada T., Okada T., et al. MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells. World J Gastroenterol 2010, 16:5334-5341.
34. Guiu B., Deschamps F., Boulin M., et al. Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Cardiovasc Intervent Radiol 2012, 35:1102-1108.
35. Zhang J.B., Chen Y., Zhang B., et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol 2011, 23:787-793.
36. Ju M.J., Qiu S.J., Fan J., et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol 2009, 44:635-642.
37. Jiang J., Nilsson-Ehle P., Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 2006, 5:4.
38. Sato T., Iwaki M., Shimogaito N., Wu X., Yamagishi S., Takeuchi M. TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 2006, 6:351-358.
39. Hyogo H., Chayama K., Yamagishi S. Nonalcoholic fatty liver disease and cardiovascular disease. Curr Pharm Des 2014, 20:2403-2411.
40. Takino J., Kobayashi Y., Takeuchi M. The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity. J Gastroenterol 2010, 45:646-655.
41. Choei H., Sasaki N., Takeuchi M., et al. Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol 2004, 108:189-193.
42. Sato T., Shimogaito N., Wu X., Kikuchi S., Yamagishi S., Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2006, 21:197-208.
43. Takeuchi M., Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008, 14:973-978.
44. Abe R., Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008, 14:940-945.
45. Takino J., Yamagishi S., Takeuchi M. Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J Gastroenterol 2012, 18:1781-1788.